Overall, survivin was expressed at moderate to strong levels in 10/58 (17%) of IBC, compared to 60 of 102 (60%) of patients with DCIS (P=0.0001; Table 1). This evidence concerns the gene BIRC5 and ductal breast carcinoma in situ.